The treatment
AVLX-144
Clinical trials progressing
We are a biotechnology company developing innovative treatments for acute conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH). In October 2020 we administered a first dose of our lead compound AVLX-144 to a human volunteer in a Phase 1 clinical study.
Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular form of stroke and an orphan indication. Based on positive results from our extensive preclinical characterization of AVLX-144 and our first clinical trials results we are convinced that we have a unique opportunity to make a transformative difference for patients,
Current Status
AVLX-144
18
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
18k
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
124m
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
18k